Validating the Predictive Value (of Response to Rituximab Induction and Maintenance) of the FCGR3A 158V/F Polymorphism Using Complimentary Genotyping Methods
18 Years
N/A
Both
Lymphoma
Trial Information
Validating the Predictive Value (of Response to Rituximab Induction and Maintenance) of the FCGR3A 158V/F Polymorphism Using Complimentary Genotyping Methods
OBJECTIVES:
Primary
- Genotype the full cohort of samples available from the RESORT clinical trial
(ECOG-E4402) for FCGR3A 158V/F in parallel to independently verify results.
- Correlate the FCGR3A 158V/F polymorphisms to response, response duration, and time to
rituximab resistance.
Secondary
- Quantify copy number variation in FCGR3A in this cohort.
OUTLINE: Archived DNA samples isolate from peripheral blood mononuclear cells and from
formalin-fixed paraffin-embedded tissue samples are analyzed for FCGR3A 158V/F polymorphisms
using different complementary genotyping methods. Assay results are reviewed and compared
with patients' outcome data.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosed with indolent follicular lymphoma
- Treated on RESORT trial (ECOG-E4402) comprising rituximab monotherapy and then
randomized to rituximab maintenance therapy or retreatment with rituximab upon
disease relapse
- Blood and tissue samples from patients available
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Correlation of FCGR3A 158V/F polymorphisms with response, duration of response, and time to rituximab resistance
Principal Investigator
Brad S. Kahl, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Wisconsin, Madison
Authority:
Unspecified
Study ID:
CDR0000701978
NCT ID:
NCT01381705
Start Date:
June 2011
Completion Date:
Related Keywords:
- Lymphoma
- recurrent grade 1 follicular lymphoma
- recurrent grade 2 follicular lymphoma
- Lymphoma
- Lymphoma, Follicular
Name | Location |
|---|
